Hepion Pharma Shares Encouraging Biomarker Data From NASH Trial
Hepion Pharmaceuticals Inc (NASDAQ: HEPA) has announced additional efficacy data from its Phase 2a AMBITION clinical trial.
Hepion Pharmaceuticals Highlights Data From Phase 2a ‘AMBITION’ Trial; Says, As Previously Reported, All Primary Endpoints Were Met
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic
21 Stocks Moving in Monday’s Pre-Market Session
Gainers
Itamar Medical Ltd. (NASDAQ: ITMR) rose 43% to $29.52 in pre-market trading. Zoll Medical said it has signed an agreement to acquire Itamar Medical for $31 per ADS in cash.
Why Are Hepion Pharma Shares Moving Higher Premarket Monday?
Hepion Pharmaceuticals Inc (NASDAQ:HEPA) stock is moving higher during premarket ahead of additional data from its non-alcoholic steatohepatitis (NASH) trial. Today,…
The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs
Biotech stocks retreated in the holiday-shortened week ending Sept. 10, reversing course from the previous week.
Hepion Pharmaceuticals Schedules Conference Call To Review Data From Phase 2a ‘AMBITION’ Clinical Trial Of CRV431 in NASH
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen’s Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 19)
The Daily Biotech Pulse: Pfizer’s Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 3)